Blocking Monoclonal Antibodies Against a GPCR Target

THE CHALLENGE

Genovac was interested in pursuing an internal campaign to develop a functional, antagonistic antibody against a GPCR protein called human FPR2 (N-formyl peptide receptor 2), also known as FPRL1 (N-formyl peptide receptor-like 1). This target is challenging because it is a multi-transmembrane spanning protein with relatively small extracellular N-terminal domains.